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Summary 
 
Title:  Importance of Heart Ultrasound in Pulmonary Embolism Diagnostic Algorithm 
Name:  Ivan Beluškov 
 
Pulmonary embolism (PE) is according to the Guidelines on the diagnosis and management of 
acute pulmonary embolism a common cardiovascular emergency. By occluding the pulmonary 
arterial bed it may lead to acute life-threatening but potentially reversible right ventricular 
failure. PE is a difficult diagnosis that may be missed because of non-specific clinical 
presentation. PE is not a disease on its own rather it is a complication of other systemic 
hypercoagulability states; Such as deep vein thrombosis (DVT), pregnancy, smoking, cancer, 
hormone replacement therapy, contraception, genetic factors and many more. Due to this fact 
and due to the fact that it usually presents with nonspecific symptoms, PE diagnosis is sometimes 
very difficult. Acute PE is usually a consequence of primarily haemodynamic problems and can 
be seen in when as much as 30-50% of the pulmonary arterial bed is occluded by thrombus. 
Symptoms of PE are usually nonspecific and this makes the diagnosis of PE a hard one to make 
even in this day and age.  The clinical presentation has a high importance in order to interpret the 
diagnostic test results and to plan the diagnostic strategies. In as much as 90 % of cases suspicion 
on PE is raised because of the presence of symptoms such as dyspnoea, chest pain and syncope, 
either singly or in combination. From all the symptoms pleuritic chest pain, whether or not 
combined with dyspnoea, is one of the most frequent presentations of PE. The levels of the D-
dimer, compression ultrasonography and computed tomographic venography, as well as 
computed tomography which if it shows that a thrombus is shown up to the segmental level than 
it can be taken as good evidence for PE, are other diagnostic tools that can be used to diagnose 
DVT and PE, “Ventilation–perfusion scintigraphy is a robust and well-established diagnostic test 
for suspected PE. Pulmonary angiography is one of the more reliable diagnostic procedures of 
PE but its invasiveness limits its use to times when noninvasive tests don’t yield satisfactory 
results. We today have available tools to guide us and support our decision making; we have 
tools to classify the stability of our patients, and with diagnostic tools such as heart ultrasound, 
which is most important for patient suffering from high-risk PE, we can do bedside evaluation of 
the patient and appropriate treatment would be given to the patient on time. The availability of 
diagnostic tools as well as the availability of different treatment options will hopefully in the 
future give us the ability to even better understand this complication and treat the underlying 
cause of it.  
Keywords: Heart Ultrasound, Pulmonary Embolism, Algorithm, Diagnosis, Venous 
Thromboembolism, Hypercoagulability. 
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Pulmonary Embolism  
What is pulmonary embolism? Pulmonary embolism (PE) is according to the Guidelines on the 
diagnosis and management of acute pulmonary embolism a common cardiovascular emergency. 
By occluding the pulmonary arterial bed it may lead to acute life-threatening but potentially 
reversible right ventricular failure. PE is a difficult diagnosis that may be missed because of non-
specific clinical presentation. [1] PE is not a disease on its own rather it is a complication of 
other systemic hypercoagulability states; Such as deep vein thrombosis (DVT), pregnancy, 
smoking, cancer, hormone replacement therapy, contraception, genetic factors and many more. 
Due to this fact and due to the fact that it usually presents with nonspecific symptoms, PE 
diagnosis is sometimes very difficult.  
 
 
Figure 1:Predisposing factors for venous thromboembolism,                    
"With permission of Oxford University Press (UK) © European Society of 
Cardiology, www.escardio.org/guidelines."Cardiology, www.escardio.org/guidelines.
" 
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Dalen JE believes that we will discover additional genetic defects that lead to hypercoagulability, 
such that the majority of patients with venous thromboembolism (VTE) will be found to have a 
hypercoagulable state.[2] According to some data even up to 50% of patient that have 
symptomatic DVT have ventilation perfusion scan that suggests high chance of having PE.[3] It 
is difficult to estimate the proportion of cases of PE that are undiagnosed, and it is due to this that 
the true incidence of PE is underreported in my opinion. Undiagnosed and untreated PE can have 
dire consequences for any patient, and for the doctor that examines this patient. It can be as much 
as 10% of patient that have symptomatic PE will die in the first 1 hour. [3][4][5] And on the 
other hand in Barritt and Jordan’s trial , 26% (5 of 19) of untreated patients with clinically 
diagnosed PE (severe end of the spectrum) died of PE during a follow-up period of ≈2 weeks, 
and another 26% of patients experienced nonfatal recurrences.[3][6] 
 
 
Figure 2: Incidence of PE per year in United States, 
With permission of  “Copyright © 2002, American College of Chest Physicians” 
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Guidelines on the Diagnosis of Pulmonary Embolism 
Acute PE is usually a consequence of primarily haemodynamic problems and can be seen in 
when as much as 30-50% of the pulmonary arterial bed is occluded by thrombus. [1][7] In the 
Guidelines on the diagnosis and management of acute pulmonary embolism it also says that non-
thrombotic pulmonary emboli are rare and have different pathophysiological consequences and 
clinical characteristics. [1] As it was said previously symptoms of PE are usually nonspecific and 
this makes the diagnosis of PE a hard one to make even in this day and age.  One of the first 
things that need to be considered when examining a patient suspected on having PE is to go over 
the clinical presentation. The clinical presentation has a high importance in order to interpret the 
diagnostic test results and to plan the diagnostic strategies. In as much as 90 % of cases suspicion 
on PE is raised because of the presence of symptoms such as dyspnoea, chest pain and syncope, 
either singly or in combination. From all the symptoms pleuritic chest pain, whether or not 
combined with dyspnoea, is one of the most frequent presentations of PE. [1]    
 
Figure 3:Prevalence of symptoms and signs in patients suspected PE according to final diagnosis "With permission of Oxford 
University Press (UK) © European Society of Cardiology, www.escardio.org/guidelines."Cardiology, www.escardio.org/guidelines." 
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The clinical presentation of a patient can neither confirm for us of exclude the diagnosis of PE, 
but it can lead us to proceed to using other diagnostic tools to make a definite diagnosis.  
  
 
Another diagnostic test that can be used to increase the probability of PE is the plasma D-dimer 
levels. The levels of the D-dimer will be elevated if there is acute clot formed. But because this is 
not the only reason why the level of D-dimers can be elevated we cannot use this test to confirm 
PE, but rather we can use it to either to increase or decrease the probability of PE depending on 
the D-dimer levels. Because negative D-dimer result can be said that safely excludes PE. [1] 
Compression ultrasonography and computed tomographic venography are other diagnostic tools 
that can be used to diagnose DVT and PE, as well as computed tomography which if it shows 
that a thrombus is shown up to the segmental level than it can be taken as good evidence for 
Figure 4: Clinical predicted rules for PE; "With permission of Oxford University Press (UK) © European Society of 
Cardiology, www.escardio.org/guidelines."Cardiology, www.escardio.org/guidelines." 
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PE.[1] “Ventilation–perfusion scintigraphy is a robust and well-established diagnostic test for 
suspected PE.”[1] It is a safe test with little or no side effects. This test is one of the better ones 
because normal scan can safely exclude where as high-probability ventilation–perfusion scan 
establishes the diagnosis of PE with high probability. [1] Pulmonary angiography is one of the 
more reliable diagnostic procedures of PE but its invasiveness limits its use to times when 
noninvasive tests don’t yield satisfactory results. [1]    
 
 
So far I have discussed some of the most commonly used and most reliable tests in order to 
diagnose PE. The only diagnostic tool that I have not discussed so far is heart ultrasound, which 
is the main topic for this paper. In the upcoming part of this paper I will shortly try to emphasize 
why heart ultrasound is important and where does it find its place in the diagnostic algorithm of 
PE.  
Figure 5: Proposed diagnostic algorithm for patients with suspected high risk PE;"With permission of Oxford 
University Press (UK) © European Society of Cardiology, www.escardio.org/guidelines."Cardiology, www.escardio.org/guidelines." 
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Heart Ultrasound as a Diagnostic Tool for Pulmonary Embolism 
Acording to Ruxandra Jurcut: “For decades, the right ventricle (RV) has been considered 
‘dispensable’ for cardiac function and consequently ignored. Echocardiography, being non-
invasive, widely available, relatively inexpensive, and having no side effects, is the modality of 
choice for the assessment of morphology and function of the RV in clinical practice. Recent 
developments have provided several new methods for analysing the RV, each having advantages 
and disadvantages. Doppler myocardial imaging (DMI), speckle tracking, or 3D 
echocardiography (3D Echo) are some of the techniques that may now add to a better 
understanding of RV function.”[8] On the other hand we have A. Torbicki who says that the 
place of echocardiography in diagnostic assessment of patients with suspected pulmonary 
embolism is neither strong nor definitely established. But if we have a patient that is acutely 
unstable echocardiography may be highly suggestive of PE. [9] This approach had been formally 
accepted by a multidisciplinary ESC Task Force and published in the ESC Guidelines in 
2000.[9][10] In most of the cases heart ultrasound gives indirect signs of PE. There are some 
signs and among them the McConnell's (defined as right ventricular (RV) free wall hypokinesis 
in the presence of normal RV apical contractility) and “60/60 sign” (acceleration time below 
60ms in the presence of tricuspid insufficiency pressure gradient (TIPG) above 30 but below 
60mmHg) are the most reliable ones and combining them together gives more reliable data on 
which we can diagnose PE.  At least 25% of patient with PE have RV dilatation.[1] The criteria 
for heart ultrasound in the diagnosis of PE have been different in different trials but are usually 
based on the RV dimensions and the tricuspid jet velocity of insufficiency. The sensitivity of it 
was 60-70% which means that a negative result cannot exclude PE. [1] Even thou heart 
ultrasound is not routinely used as a diagnostic test its use is really helpful in finding patients 
12 
 
with PE that have poor prognosis. It can also be used for rapid and accurate risk assessment. And 
based on the severity of RV hypokinesis, persistent pulmonary hypertension, a patent foramen 
ovale, and free-floating right-heart thrombus are echocardiographic markers that identify the risk 
of a patient for recurrent thromboembolism. [11] Bedside echocardiography is really useful in 
emergency decision making. Because if we have a patient with hypotension and shock the 
absence of RV overload with high probability excludes PE.[1] And it lies in this point the 
importance of heart ultrasound, because according to this prognosis the treatment of PE is guided 
and further prognostic stratification is done based on the echocardiography imaging results.  
 
 
 Figure 6: Echocardiographic signs, "With permission of Oxford University Press (UK) © European Society of 
Cardiology, www.escardio.org/guidelines."Cardiology, www.escardio.org/guidelines." 
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It is because of this that in the figure below that summarizes the guidelines on the diagnosis and 
management of acute pulmonary embolism in patients suspected of non-high risk PE [1], we 
don’t see heart ultrasound as a diagnostic tool. Whereas as we saw in the figure summarizing the 
patients suspected of high risk PE heart ultrasound is after CT, which in this case is not 
immediately available due to the need of bedside diagnosis, most reliable and available for 
bedside diagnosis and fast assessment. This makes heart ultrasound indispensable tool in the 
algorithm for diagnosis and management of PE. 
  
 
 
 
Figure 7: Proposed diagnostic algorithm for patients with suspected non high risk PE "With permission of Oxford 
University Press (UK) © European Society of Cardiology, www.escardio.org/guidelines."Cardiology, www.escardio.org/guidelines." 
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Prognostic Assessment of the Patient with Pulmonary Embolism 
Acute PA caries huge burden on the health and the survival of the patient as well as on the health 
care system. Because of this we need to asses every patient fast and with great care in order to 
benefit both the patient and system from unwanted complications and difficult recovery, and to 
ensure the highest quality of care. [12] One of the major issues in the assessment of patients with 
PE is to accurately assess the risk in order to prevent the early death of the patient. We can do 
this as we previously said with heart ultrasound assessment of the RV, in order to determine its 
dysfunction and overload. [12][13] [14] In their critical review paper Stavros Konstantinides and 
Samuel Z. Goldhaber explain and define the initial prognostic assessment as: “The definition of 
high-risk (European classsification) or massive (North American classification) PE is usually 
straightforward and relies on the presence of clinically overt RV failure which results in 
haemodynamic compromise. This condition, which is encountered in <5% of all patients 
presenting with acute PE, constitutes a medical emergency, since it is associated with at least a 
15% risk of in-hospital death, particularly during the first hours after admission.”[12] Heart 
ultrasound can detect the morphological changes and function of the RV. And Stavros 
Konstantinides and Samuel Z. Goldhaber  have found registries of cohort studies that make the 
connection between heart ultrasound parameters of RV dysfunction and  poor in-hospital 
outcome.[12] But this is only true for haemodynamically unstable patients. Additional clinical 
signs are needed to indicate severe PE in haemodynamically stable patients. Circulating 
biochemical markers and especially circulating natriuretic peptides are additional tools for 
assessing these haemodynamically stable patients and assessing and stratifying their risk. [12] 
Stavros Konstantinides and Samuel Z. Goldhaber  also found that: “A meta-analysis of 13 
studies found that 51% of 1132 patients with acute PE had elevated brain natriuretic peptide 
15 
 
(BNP) or N-terminal (NT)-proBNP concentrations; these were associated with an increased risk 
of early death and a complicated in-hospital course.”[12][15] Other diagnostic test such as levels 
of troponin I or T can be used based on meta-analysis of published studies, as well as Heart-type 
fatty acid-binding protein, Cardiac expression of growth-differentiation factor-15 which both 
appear to be promising in the evaluation of the prognosis of patients with non-high risk PE.[12] 
All of these tools and many more are summarized in the figures below, and combining these 
tools is as important in the assessment of the prognosis of patients with PE.[12] 
 
Figure 8: Risk assessment tools in acute PE;"With permission of Oxford University Press (UK) © European Society of 
Cardiology. " 
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Figure 9: Thrombolysis for PE; "With permission of Oxford University Press 
(UK) © European Society of Cardiology." 
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Treatment  
So far we have discussed the most important points in assessing the risk posed by PE, but we 
have not said much about how we should manage and what the treatment of these patients should 
be. After assessing and stratifying the risk of our patients there are many possibilities today how 
to treat these patients, and one of the most commonly used in acute settings is heparin 
anticoagulation. Heparin anticoagulation is used in different regiments and the current regiments 
are summarized in the figure below.[12] Besides Heparin anticoagulation we can also use 
Vitamin K antagonists and other new oral anticoagulants in the treatment of PE. 
 
 Figure 10: Anticoagulation regiment for acute PE; "With 
permission of Oxford University Press (UK) © European Society of Cardiology " 
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Other than heparin anticoagulation we have thrombolysis as a tool for treatment of PE, and it has 
been shown constantly that is effectively resolves the obstruction made by the thrombus and the 
hemodynamic functions.[12] Overall, >90% of patients with PE appear to respond favourably to 
thrombolysis as indicated by clinical and echocardiographic improvement within the first 36 
h.[12][16]  
 
We now have several thrombolysis regiments available to us, as seen in figure 9 of the previous 
section, and it has been shown that in studies that thrombolysis works best if treatment is 
initiated within 48 h of symptom onset, but thrombolysis can still be useful in patients who have 
had symptoms for 6–14 days.[12][17] 
 
Other treatments available for PE are surgical or interventional treatment, but these treatment 
options for now should be considered and are recommended only in situations when there is 
absolute contraindication to thrombolysis or if thrombolysis treatment failed and the patient has 
high-risk PE. Inferior vena cava filters on the other hand are not per say treatment options rather 
a means of both primary and secondary prevention of PE in patient suffering fr1om 
hypercoagulable states, however there is not enough date to support their use and safety. [12]  
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Conclusion 
Even thou the fatality of PE continues to decrease and today we have diagnostic tools that are 
more efficient and help us differentiate the severity of PE, we still need to improve our 
knowledge on PE in order to decrease the burden of PE on health and survival. [18] We today 
have available tools to guide us and support our decision making; we have tools to classify the 
stability of our patients, and with diagnostic tools such as heart ultrasound, which is most 
important for patient suffering from high-risk PE, we can do bedside evaluation of the patient 
and appropriate treatment would be given to the patient on time. It is my opinion that in the 
future heart ultrasound as a tool can be further improved, the interpretations and understandings 
of heart ultrasound signs can be further improved, and as such this tool it can be used not only in 
the management of high-risk PE patients, but also in low and intermediate risk PE. It is John 
Locke that said: “The improvement of understanding is for two ends: first, our own increase of 
knowledge; secondly, to enable us to deliver that knowledge to others.” 
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